期刊文献+

卟啉病相关胆色素原脱氨酶基因的克隆与原核表达

Porphobilinogen deaminase of porphyria cloning and prokaryotic expression
下载PDF
导出
摘要 目的主要为了获得胆色素原脱氨酶(PBGD)在大肠杆菌中的原核重组表达蛋白,并对其进行纯化,为下一步研究PBGD结构及功能提供实验基础。方法以人细胞中的总RNA逆转录得到的c DNA为模板,PCR扩增,构建p ET28a(+)-PBGD重组质粒。把含有外源片段的p ET28a-PBGD重组质粒转入大肠杆菌BL21中进行诱导表达,经His纯化方法获得高纯度的PBGD融合蛋白。结果 PCR扩增出大小约1 500 bp的特异PBGD c DNA片段;成功构建了p ET28a(+)-PBGD融合表达载体;该表达载体融合表达的蛋白分子量约为44 k D,且大部分纯化蛋白存在于包涵体中。胆色素原脱氨酶的酶活性检测中发现,PBGD的最适酶反应温度为36℃,最适酶反应p H为7.5。结论该实验已成功地克隆出编码正确的PBGD基因片段,并构建了高效原核融合表达载体:p ET28a(+)-PBGD。获得PBGD在大肠杆菌中表达的重组蛋白,并纯化至均一,为PBGD结构和功能的研究提供基础。 [Objective] Express and purify Prophobilinogen Deaminase (PBGD) in E. coli and provide basis for the study of structure and function of PBGD. [Methods] Human cell RNAs were extracted and reverse transcribed to cDNA. PBGD was amplified and inserted into prokaryotie expression vector pET28a (+). The recombinant vector was transformed into BL21. PBGD expression was then induced by IPTG. The expressed His6-tagged protein was purified by Ni2+ affinity chromatography column and characterized by SDSPAGE and Western blotting. [Results] PBGD 1 500 bp gene was amplified and sequencing result was correct; the pET28a (+)-PBGD recombinant vector was successfully constructed; SDS-PAGE analysis showed that the fusion protein was about 44 kD, and a small portion of the protein was expressed in the supernatant; the best temperature for PBGD is 36℃, and the optimum pH of PBGD is 7.5. [Conclusion] The PBGD gene was successfully cloned into pET28a (+) expression vector and purified by Ni2+ affinity chromatography column.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2014年第32期19-24,共6页 China Journal of Modern Medicine
关键词 卟啉病 胆色素原脱氨酶 重组蛋白 基因工程 porphyria porphobilinogen deaminase recombinant protein genetic engineering
  • 相关文献

参考文献14

  • 1TRAN TP, LEDUC K, SAVARD M, et al. Acute porphyria pre- senting as epilepsia partialis continua[J]. Case Rep Neurol, 2013, 5(2): 116-124.
  • 2KUMAR B. Acute intexmittent porphyria presenting solely with psychosis: a case report and discussion[J]. Psychosomatics, 2012, 53(5): 494-498.
  • 3NABINL A, THAPAR J, PAUDEL, ct al. Acute intermittent por-phyria with SIADH and fluctuating dysautonomia[J]. Kathmandu Univ Med J (KUMJ), 2012, 10(38): 96-99.
  • 4STEINM PE, BADMINTONJ N, BARTH H, et al. Acute inter- mittent porphyria: fatal complications of treatment[J]. Clin Med, 2012, 12(3): 293-294.
  • 5FERRER MD, TAULER P, SURED A, et al. Antioxidants restore protopot~phyrinogen oxidase in variegate porphyria patients[J]. Eur J Clin Invest, 2013, 43(7): 668-678.
  • 6JAINK RS, NAGPALA V. Challenges in the diagnosis and treat- ment of a case of acute intermittent porphyria in india[J]. J Postgr~l Med, 2013, 59(4): 338-339.
  • 7MEISSNERA PN, CORRIGALLR V, HIFI? J. Fifty years of por- phyria at the University of Cape Town[J]. S Afr Med J, 2012, 102(6): 422-426.
  • 8UNZU C, SAMPEDRO IA, MAULEON I, et al. Helper-depen- dent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice[J]. Hum Mal Genet, 2013, 22(14): 2929-2940.
  • 9Y1NS Z, WAHLIN S, ELLIS EC, et al. Hepatocyte transplanta-.tion ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria[J]. Cell Transplant, 2013.
  • 10RIMINTON C. Spectral absorption coefficient of some porphyrins in the soret-band region[J]. Biochem J, 1960, 75: 620-823.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部